IA
TVTX icon

IFP Advisors’s Travere Therapeutics TVTX Stock Holding History

IFP Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Sell
2,240
-58
-3% -$2.57K ﹤0.01% 1807
2026
Q1 		$68.3K Sell
2,298
-76
-3% -$2.27K ﹤0.01% 2077
2025
Q4 		$90.7K Buy
2,374
+2,354
+11,770% +$76.5K ﹤0.01% 1866
2025
Q3 		$478 Buy
+20
New +$376 ﹤0.01% 4183
2025
Q2 		– Sell
-17
Closed -$282 – 4254
2025
Q1 		$305 Hold
17
– – ﹤0.01% 3560
2024
Q4 		$296 Buy
+17
New +$301 ﹤0.01% 3570
2021
Q2 		– Sell
-40
Closed -$789 – 3239
2021
Q1 		$1K Sell
40
-43
-52% -$1.19K ﹤0.01% 2886
2020
Q4 		$3K Buy
83
+19
+30% +$444 ﹤0.01% 2531
2020
Q3 		$1K Hold
64
– – ﹤0.01% 2726
2020
Q2 		$1K Hold
64
– – ﹤0.01% 2625
2020
Q1 		$1K Hold
64
– – ﹤0.01% 2622
2019
Q4 		$1K Buy
+64
New +$817 ﹤0.01% 2731

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

IFP Advisors's TVTX Position: Q2 2026 in Review

IFP Advisors reduced its Travere Therapeutics (TVTX) stake by 2.5% in Q2 2026, selling an estimated $2.57K and leaving 2,240 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1807.

IFP Advisors first reported a position in TVTX in Q4 2019 and has held it in 12 quarters since. 26 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • IFP Advisors held 2,240 shares of Travere Therapeutics worth $127K as of Q2 2026.
  • IFP Advisors sold 58 Travere Therapeutics shares in Q2 2026, an estimated $2.57K.
  • Travere Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #1807 holding.
  • IFP Advisors first reported a position in Travere Therapeutics in Q4 2019 and has held it in 12 quarters since.
  • 26 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.